Ypsomed Holding AG (SWX:YPSN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 3.82B |
| Revenue (ttm) | 787.55M |
| Net Income (ttm) | 194.00M |
| Shares Out | 13.65M |
| EPS (ttm) | 14.21 |
| PE Ratio | 19.68 |
| Forward PE | 19.75 |
| Dividend | 2.20 (0.79%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 16,020 |
| Average Volume | 18,217 |
| Open | 283.80 |
| Previous Close | 279.40 |
| Day's Range | 278.20 - 284.80 |
| 52-Week Range | 260.50 - 441.50 |
| Beta | 0.76 |
| RSI | 43.85 |
| Earnings Date | May 20, 2026 |
About Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insu... [Read more]
Financial Performance
In fiscal year 2025, Ypsomed Holding AG's revenue was 748.87 million, an increase of 36.54% compared to the previous year's 548.46 million. Earnings were 87.50 million, an increase of 11.66%.
Financial StatementsNews
Ypsomed Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined a strategic shift to a pure-play injection device business, driven by strong growth in injectables, biosimilars, and GLP-1 therapies. Financial targets include doubling sales by 2030, maintaining high margins, and expanding global production, with risks mainly in execution and market volatility.
Ypsomed Holding AG Transcript: H1 25/26
Strong H1 results driven by 21% core sales growth, 32.4% EBIT margin, and strategic focus on B2B injection devices. Guidance for 20% annual sales growth and >30% EBIT margin is confirmed, with major capacity expansion and innovation underway.
Ypsomed Holding AG Transcript: H2 24/25
Exceeded sales and profitability targets with 37% revenue growth, driven by delivery systems and global capacity expansion. Divestment of diabetes care and strong project pipeline position the company for 20% growth and higher EBIT next year.
Ypsomed Holding AG Transcript: Investor Update
A CHF 420 million deal to divest the Diabetes Care business to TecMed AG will transform the company into a pure-play injection system specialist, with proceeds funding core business expansion and no special dividend planned. The transaction includes an earn-out tied to sales, continued contract manufacturing, and significant operational shifts in Solothurn and Burgdorf.
Ypsomed Holding AG Transcript: H1 24/25
Strong revenue and EBIT growth driven by delivery systems and diabetes care, with continued global expansion and a solid balance sheet. Strategic divestments and a robust project pipeline support a positive outlook, with guidance reaffirmed for 25% top-line growth and CHF 140 million EBIT.